Clinical trials: Alzheimer's
Caregiver Stress
Mindfulness-based Cognitive Coping for ADRD Caregivers
This project will evaluate the effectiveness of the Mindfulness-based Cognitive Coping (MCC) intervention to alleviate stress and depressive symptoms of caregivers of Individuals with Alzheimer's Disease and Related Dementia.
- Trial name
- NCT05979922
- Testing
- Mindfulness-based Cognitive Coping, Traditional Educational/Resources Program
- Where
- United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Photozig, Inc.
Alzheimer Disease
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are…
- Trial name
- NCT00912288
- Testing
- Dimebon 20 mg po TID
- Where
- 47 sites in United States, Canada and 6 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Alzheimer's Disease
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00362024
- Testing
- MK0952
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease, Dementia of Alzheimer Type
DMB-I in the Treatment of Alzheimer Type Dementia
The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.
- Trial name
- NCT06292351
- Testing
- DMB-I (Dimebon)
- Where
- 7 sites in Russia
- Volunteers
- 133 people
- Sponsor
- Bigespas LTD
Alzheimer's Disease
Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)
This study is a Phase 2, randomized, placebo-controlled, dose-ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety…
- Trial name
- NCT02615002
- Testing
- Piromelatine
- Where
- 56 sites in United States
- Volunteers
- 371 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Alzheimer Disease (AD)
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
- Trial name
- NCT03518073
- Testing
- Zagotenemab
- Where
- 60 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Early Onset
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants…
- Trial name
- NCT07328451
- Testing
- DNL628
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Denali Therapeutics Inc.
Alzheimer's Disease
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).
- Trial name
- ExpeditionPRO (NCT02760602)
- Testing
- Solanezumab
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
This study will investigate safety, tolerability and pharmacokinetics of ABT-126 in up to 20 male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's disease on stable doses of…
- Trial name
- NCT01482845
- Testing
- ABT-126
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Abbott
Alzheimer Disease or Associated Disorder, Dementia
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
The goal of this pilot randomized controlled trial is to assess the impact of D2D rideshare services with a trained companion driver on the rate of medical appointments for older adults and individuals with AD/ADRD.
- Conditions
- Alzheimer Disease or Associated Disorder, Dementia, Cognitive Decline
- Trial name
- NCT06850870
- Testing
- Door-through-door companion rideshare, Curb-to-curb rideshare services
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Onward Health, Inc
Alzheimer's Disease
Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease
Brief summary: This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of AD-35 tablet in patients with mild to moderate Alzheimer's Disease.
- Trial name
- WAY (NCT03790982)
- Testing
- AD-35 60 mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Early Alzheimer's Disease
A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
The primary objective of the study is to evaluate the effects of hepatic impairment on the pharmacokinetics (PK) of E2609 after a single dose administration.
- Trial name
- NCT02859207
- Testing
- E2609
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Alzheimer's Disease
18F-AV-1451 High Resolution Autopsy Study
The study is designed to examine the relationship between imaging results detected on a 18F-AV-1451 PET scan and pathology found at autopsy within six months of imaging.
- Trial name
- NCT02350634
- Testing
- Flortaucipir F18
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
Approximately 90 patients, aged 50 to 80 years, with a diagnosis of early Alzheimer's disease will take part in this research study. This study will be conducted in the US.
- Trial name
- EAD501 (NCT05607615)
- Testing
- Hydroxypropyl Beta Cyclodextrin
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Cyclo Therapeutics, Inc.
Alzheimer's Disease
Study of Magnetic Fields to Treat Alzheimer's Disease
To determine if low level magnetic fields can help to improve memory in patients diagnosed with Alzheimer's disease.
- Trial name
- NCT01313806
- Testing
- Resonator
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- pico-tesla Magnetic Therapies, LLC
Alzheimer Disease
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective…
- Trial name
- NCT01020838
- Testing
- Florbetaben (BAY94-9172)
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer Disease, Late Onset
Tdap and Biomarkers of Alzheimer's Disease
Recently, the Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccination was added to the list of immunizations associated with lower incidence of dementia.
- Trial name
- NCT05183516
- Testing
- tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Mindful Diagnostics and Therapeutics, LLC
Healthy Volunteers, Alzheimer Disease
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study.
- Trial name
- NCT02323334
- Testing
- LY3202626, Itraconazole
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's disease over a treatment period of 12-weeks and the course of any potential effects during a…
- Trial name
- NCT00810147
- Testing
- BMS-708163
- Where
- 41 sites in United States, Denmark and 2 more
- Volunteers
- 209 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease, Hearing Loss
Hearing Instruments in Alzheimer's Disease
There is a strong connection between hearing loss and cognitive impairment, particularly dementia, in old age. Worldwide, dementia affects approximately 5% of persons over the age of 65 years.
- Trial name
- HIAD (NCT02294513)
- Testing
- Standard audiologic rehabilitation (incl. HI)
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Phonak AG, Switzerland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.